Skip to main content
. 2017 Jul 26;8(45):78452–78465. doi: 10.18632/oncotarget.19632

Figure 2. Establishment of volasertib-resistant cells and resistant mechanism of volasertib.

Figure 2

(A) The GI50 values of volasertib in both the parental and the volasertib-resistant cells. Error bars represent the mean values ± S.D. of at least three independent experiments. (B) The cell cycle analysis in both the parental and the volasertib-resistant cells after volasertib administration. (C) The protein expressions of PLK1 and Wee1 were evaluated by immunofluorescent staining. Both parental and volasertib-resistant MOLM14 and HL-60 cells were treated with 50 nM volasertib for 18 hours.